Evidence map›Paper›PMID 41255577›Full record

ReviewJuntendo medical journal2025

Is Antithrombin Supplementation Effective in Suppressing ECMO Circuit Thrombosis in Sepsis?

Jerrold H Levy, Nao Umei, Yutaka Kondo, Michio Mineshima, Toshiaki Iba

Abstract readReview
In one paragraph

Review in Juntendo medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jerrold H Levy
Nao Umei
Yutaka Kondo
Michio Mineshima
Toshiaki Iba

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracorporeal membrane oxygenation (ECMO) is increasingly used for the management of severe sepsis-induced cardiopulmonary failure. Despite standard heparin anticoagulation, circuit thrombosis remains a significant complication. Antithrombin (AT), a critical serine protease inhibitor and cofactor for heparin, is often low in septic patients, especially during ECMO, raising concerns about the efficacy of heparin-based anticoagulation. This review explores the role of AT supplementation to suppress ECMO circuit thrombosis in sepsis, integrating epidemiological data, underlying pathophysiology, preclinical research, and clinical evidence. While theoretical rationale and some observational data support the supplementation of AT, definitive clinical trials are lacking. We conclude by outlining future perspectives and research needs to clarify the role of AT in ECMO management for septic patients.

Indexed as

antithrombincoagulationextracorporeal membrane oxygenationsepsisthrombosis

Identifiers

PMID41255577
PMCPMC12620714

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.